Pharma
Rare Disease: 2023 in Review
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings. In the last five years, our consultants have undertaken over 700 client projects in rare diseases, constituting over 20% of our...
ON Helix 2024
ON Helix Life Science Conference 2024
Evolving business models: Pharmaceutical incubators
As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large biopharmaceutical companies were sourced externally in 2020. Sources of external innovation...
AI in drug discovery and development: Will it live up to the hype?
The recent explosion of generative artificial intelligence (AI) has fueled interest in and concern over the use of AI in drug discovery and research and development. ...
Where are we now? The promises and pitfalls of solid tumor CAR-T therapy
CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth. While normal T-cells with effector features have difficulty infiltrating the complex tumor microenvironment, ex vivo reprogramm...
The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe
The Patient Preference Survey aims to understand unmet needs related to riluzole management in people with Amyotrophic Lateral Sclerosis (ALS) and to identify which characteristics of a new formulation could better match their preferences. The survey involved 117 people with ALS (PALS) ...
Source of business for biosimilars in immunology
As of August 2023, there were 40 FDA-approved biosimilar products, including 25 commercially available products and four with interchangeable status.1 Adoption of biosimilars has continued to grow each year across therapeutic areas, and the increased competition they have generated is d...
Prism facilitate sale of Cambridge-based medtech design consultancy
Prism Corporate Broking are pleased to announce that we have facilitated the sale of medtech device design and development consultancy, Springboard Pro Ltd, to leading global healthcare packaging and medical device manufacturers, Sanner GmbH (Sanner Group), a company backed by Europe’s ...
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cambridge, UK — January 2024 — Cuttsy+Cuttsy, a healthcare communication agency, is pleased to announce the appointment of Harriet Karia as its first Managing Director. This move follows a period of substantial growth and is a practical step towards the agency's future plans. In her n...
Arecor appoints Dr Helen Parris as Senior Vice President, Commercial And General Manager of Tetris Pharma Ltd
Cambridge, UK - Arecor Therapeutics plc, the biopharmaceutical company advancing today’s therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pha...